Double maintains 1 strategies that include RLAY - Relay Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 46.91% | $47.13M | 0.5% |
XBI | 46.87% | $4.76B | 0.35% |
IBB | 46.16% | $5.61B | 0.45% |
PBE | 45.86% | $224.98M | 0.58% |
ARKG | 42.75% | $936.86M | 0.75% |
FBT | 41.68% | $1.08B | 0.56% |
IWO | 41.08% | $10.72B | 0.24% |
ISCG | 41.01% | $655.02M | 0.06% |
SMOT | 40.23% | $417.35M | 0.49% |
KJUL | 40.12% | $155.05M | 0.79% |
IWC | 39.62% | $797.08M | 0.6% |
ROBO | 39.55% | $924.80M | 0.95% |
VTWO | 39.51% | $10.92B | 0.07% |
IWM | 39.51% | $62.65B | 0.19% |
VBK | 39.49% | $17.32B | 0.07% |
BBH | 39.36% | $358.88M | 0.35% |
IMCG | 39.32% | $2.51B | 0.06% |
JVAL | 39.29% | $666.54M | 0.12% |
MOAT | 39.25% | $13.40B | 0.47% |
SCHA | 39.17% | $15.94B | 0.04% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -28.49% | $195.31M | 0.85% |
TAIL | -27.22% | $87.65M | 0.59% |
BTAL | -27.19% | $416.76M | 1.43% |
CTA | -13.34% | $978.30M | 0.76% |
TPMN | -11.36% | $33.32M | 0.65% |
CLOA | -11.03% | $783.46M | 0.2% |
BIL | -10.65% | $41.88B | 0.1356% |
USDU | -9.87% | $206.96M | 0.5% |
UUP | -9.20% | $325.79M | 0.77% |
DBE | -9.05% | $55.52M | 0.77% |
OILK | -8.24% | $67.85M | 0.69% |
USL | -8.01% | $47.77M | 0.85% |
ULST | -7.88% | $585.14M | 0.2% |
BNO | -7.80% | $99.25M | 1% |
DBO | -7.62% | $202.41M | 0.77% |
UGA | -7.15% | $87.23M | 0.97% |
USO | -6.99% | $972.70M | 0.6% |
CCOR | -6.67% | $64.12M | 1.18% |
TFLO | -6.55% | $6.75B | 0.15% |
UNG | -5.42% | $397.59M | 1.06% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CGMU | -0.03% | $3.01B | 0.27% |
IBTG | -0.25% | $1.82B | 0.07% |
COM | 0.28% | $242.21M | 0.72% |
ITM | 0.32% | $1.90B | 0.18% |
GBIL | 0.33% | $6.30B | 0.12% |
OWNS | 0.39% | $134.08M | 0.3% |
IBTF | 0.39% | $2.22B | 0.07% |
BSSX | -0.45% | $76.01M | 0.18% |
XBIL | -0.45% | $706.15M | 0.15% |
FTGC | 0.68% | $2.52B | 1.02% |
BILZ | 0.68% | $734.41M | 0.14% |
VTIP | 0.77% | $13.72B | 0.03% |
SHM | 0.78% | $3.42B | 0.2% |
TBIL | 0.79% | $5.39B | 0.15% |
SPTS | 0.83% | $5.97B | 0.03% |
FLDR | 0.84% | $775.30M | 0.15% |
CANE | -0.84% | $11.28M | 0.29% |
EQLS | 0.85% | $4.80M | 1% |
BUXX | 0.88% | $234.79M | 0.25% |
DFNM | 0.88% | $1.51B | 0.17% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
XNCR | 49.76% | $691.94M | -54.37% | 0.00% |
ZWS | 46.97% | $5.65B | +3.43% | 1.11% |
BDTX | 40.07% | $89.53M | -68.40% | 0.00% |
RXRX | 39.78% | $2.13B | -40.76% | 0.00% |
SHC | 39.16% | $3.26B | -0.35% | 0.00% |
CSWI | 38.72% | $5.09B | +31.65% | 0.33% |
IMNM | 38.48% | $583.44M | -68.94% | 0.00% |
NEU | 38.17% | $5.37B | -9.34% | 1.87% |
TVTX | 37.99% | $1.59B | +157.02% | 0.00% |
ALEC | 37.46% | $116.92M | -79.97% | 0.00% |
DHR | 36.85% | $146.78B | -16.04% | 0.56% |
STKL | 36.79% | $564.05M | -29.07% | 0.00% |
KYMR | 36.36% | $1.71B | -29.01% | 0.00% |
RCKT | 36.35% | $671.77M | -75.23% | 0.00% |
DMRC | 35.81% | $283.14M | -49.46% | 0.00% |
QDEL | 35.16% | $2.34B | -18.58% | 0.00% |
HLNE | 35.13% | $6.74B | +37.35% | 1.39% |
RVTY | 35.05% | $12.82B | +4.27% | 0.28% |
NTLA | 35.01% | $755.67M | -70.78% | 0.00% |
WCC | 34.44% | $7.92B | -6.78% | 1.19% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -15.98% | $94.61B | +23.82% | 3.89% |
CBOE | -15.90% | $23.50B | +25.53% | 1.05% |
LITB | -14.65% | $41.93M | -46.48% | 0.00% |
ENR | -7.08% | $2.16B | +5.83% | 4.06% |
CL | -6.88% | $75.88B | +6.19% | 2.07% |
PLCE | -6.84% | $117.75M | -9.97% | 0.00% |
CLMT | -6.40% | $1.13B | -13.66% | 0.00% |
ACI | -6.25% | $13.00B | +5.65% | 2.22% |
MRK | -6.23% | $218.76B | -33.33% | 3.60% |
TCTM | -5.73% | $3.92M | -82.22% | 0.00% |
VTOL | -5.63% | $944.86M | +21.06% | 0.00% |
MSDL | -5.43% | $1.79B | -4.01% | 9.98% |
NNVC | -5.38% | $17.99M | -10.16% | 0.00% |
CCEC | -5.08% | $1.17B | +17.80% | 2.99% |
NEUE | -5.05% | $57.12M | +4.27% | 0.00% |
KMB | -5.00% | $47.39B | +13.36% | 3.37% |
AGRO | -4.95% | $1.14B | +2.99% | 3.01% |
FATBB | -4.39% | $56.94M | -23.78% | 14.95% |
VHC | -4.19% | $35.77M | +37.68% | 0.00% |
MNOV | -4.15% | $69.16M | -7.24% | 0.00% |
Yahoo
We recently published a list of Top 9 AI Ratings and News Updates on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other top AI ratings and news updates on Wall Street’s radar. Despite AI’s potential to transform our lives for the […]
Yahoo
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine therapy co
Yahoo
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11
Yahoo
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision me
SeekingAlpha
Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out why RLAY stock is a Buy.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RPRX | -0.01% | $13.55B | +8.61% | 2.68% |
HLF | -0.02% | $893.57M | +8.48% | 0.00% |
VREX | 0.03% | $470.92M | -36.54% | 0.00% |
OCFT | 0.03% | $248.36M | +201.34% | 0.00% |
PRGS | -0.07% | $2.54B | +14.30% | 0.61% |
PULM | -0.08% | $22.13M | +234.81% | 0.00% |
GIS | -0.13% | $32.41B | -14.20% | 3.90% |
MGPI | -0.13% | $601.74M | -65.85% | 1.80% |
VOD | -0.21% | $22.77B | +0.33% | 7.70% |
TIMB | -0.23% | $7.73B | -10.84% | 3.11% |
SPTN | 0.23% | $694.88M | +5.27% | 4.21% |
VRN | 0.23% | $4.09B | -24.09% | 5.23% |
TSN | 0.27% | $21.91B | +8.55% | 3.09% |
PG | 0.27% | $397.45B | +8.55% | 2.32% |
ABEV | -0.28% | $37.13B | -3.67% | 4.43% |
IMO | 0.30% | $37.43B | +1.56% | 2.63% |
GO | 0.33% | $1.34B | -48.40% | 0.00% |
DAO | -0.34% | $250.16M | +95.84% | 0.00% |
EW | 0.35% | $42.20B | -22.54% | 0.00% |
T | 0.35% | $201.99B | +59.80% | 3.85% |
Current Value
$2.331 Year Return
Current Value
$2.331 Year Return